CG-P5 peptide
Phase 1Peptide
CG-P5 peptide is one of 13 small molecule programs targeting Wet Macular Degeneration. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Wet Macular Degeneration
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Approved
Kenalog
BBassett Healthcare
Approved
Visudyne
BBausch Health Americas, Inc.
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Phase 2
Eylea
RegeneronPreclinical
Lucentis
RochePreclinical
Macugen
PfizerPreclinical
Beovu
NovartisPreclinical
Vabysmo
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CG-P5 peptide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Peptide[2]
- Highest Phase
- Phase 1[1]
- Company
- CCaregen Co. Ltd.